Trilaciclib for the prevention reduction of chemotherapy-induced myelosuppression in the management of extensive-stage small cell lung cancer: a profile of its use

<div><b>Declarations</b></div><div><b>Funding</b> The preparation of this review was not supported by any external funding.</div><div><br></div><div><b>Authorship and conflict of interes</b>t ES Kim, a contracted employee of Adis International Ltd/Springer Nature, and SJ Keam, a salaried employee of Adis International Ltd/Springer Nature, declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.</div><div><br></div><div><br></div><div><b>Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability</b> not applicable.</div><div><br></div><div>Additional information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews"><b>here</b></a>.<br></div><div><br></div><div><b>Abstract</b></div><div>Trilaciclib (COSELA™) is a transient inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6) that is approved in the USA to decrease the incidence of chemotherapy-induced myelosuppression (CIM) when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen in adults being treated for extensive-stage small cell lung cancer (ES-SCLC). It is the first approved therapy to provide myeloprotection, and when administered before chemotherapy, it is a valuable option for decreasing the incidence of CIM. In three clinical randomized trials, trilaciclib administration prior to standard-of-care chemotherapy for ES-SCLC reduced myelosuppression and the need for rescue interventions, improved patient-reported outcomes and the safety profile of the chemotherapy regimens, and had no impact on antitumor efficacy.<br></div><div><br></div><div>© Springer Nature Switzerland AG 2022<br></div><div><br></div>